|
1
|
Sung H, Ferlay J, Siegel RL, Laversanne M,
Soerjomataram I, Jemal A and Bray F: Global Cancer Statistics 2020:
GLOBOCAN estimates of incidence and mortality worldwide for 36
cancers in 185 countries. CA Cancer J Clin. 71:209–249.
2021.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Pham T, Bui L, Kim G, Hoang D, Tran T and
Hoang M: Cancers in vietnam-burden and control efforts: A narrative
scoping review. Cancer Control. 26(1073274819863802)2019.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Pham DX, Phung AHT, Nguyen HD, Bui TD, Mai
LD, Tran BNH, Tran TS, Nguyen TV and Ho-Pham LT: Trends in
colorectal cancer incidence in Ho Chi Minh City, Vietnam
(1996-2015): Joinpoint regression and age-period-cohort analyses.
Cancer Epidemiol. 77(102113)2022.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Alves Martins BA, de Bulhões GF,
Cavalcanti IN, Martins MM, de Oliveira PG and Martins AMA:
Biomarkers in colorectal cancer: The role of translational
proteomics research. Front Oncol. 9(1284)2019.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Tran CG, Goffredo P, Mott SL, Hart A, You
YN, Vauthey JN, Weigel RJ and Hassan I: The impact of KRAS
mutation, microsatellite instability, and tumor laterality on the
prognosis of nonmetastatic colon cancer. Surgery. 171:657–665.
2022.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Lee DW, Kim KJ, Han SW, Lee HJ, Rhee YY,
Bae JM, Cho NY, Lee KH, Kim TY, Oh DY, et al: KRAS mutation is
associated with worse prognosis in stage III or high-risk stage II
colon cancer patients treated with adjuvant FOLFOX. Ann Surg Oncol.
22:187–194. 2015.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Jones RP, Sutton PA, Evans JP, Clifford R,
McAvoy A, Lewis J, Rousseau A, Mountford R, McWhirter D and Malik
HZ: Specific mutations in KRAS codon 12 are associated with worse
overall survival in patients with advanced and recurrent colorectal
cancer. Br J Cancer. 116:923–929. 2017.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Roberts PJ and Der CJ: Targeting the
Raf-MEK-ERK mitogen-activated protein kinase cascade for the
treatment of cancer. Oncogene. 26:3291–3310. 2007.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Krasinskas AM: EGFR Signaling in
Colorectal Carcinoma. Patholog Res Int. 2011(932932)2011.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Morrison DK: MAP kinase pathways. Cold
Spring Harb Perspect Biol. 4(a011254)2012.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Avruch J: MAP kinase pathways: The first
twenty years. Biochim Biophys Acta. 1773:1150–1160. 2007.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Zhang W and Liu HT: MAPK signal pathways
in the regulation of cell proliferation in mammalian cells. Cell
Res. 12:9–18. 2002.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Therkildsen C, Bergmann TK,
Henrichsen-Schnack T, Ladelund S and Nilbert M: The predictive
value of KRAS, NRAS, BRAF, PIK3CA and PTEN for anti-EGFR treatment
in metastatic colorectal cancer: A systematic review and
meta-analysis. Acta Oncol. 53:852–864. 2014.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Misale S, Yaeger R, Hobor S, Scala E,
Janakiraman M, Liska D, Valtorta E, Schiavo R, Buscarino M,
Siravegna G, et al: Emergence of KRAS mutations and acquired
resistance to anti-EGFR therapy in colorectal cancer. Nature.
486:532–536. 2012.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Siddiqui AD and Piperdi B: KRAS mutation
in colon cancer: A marker of resistance to EGFR-I therapy. Ann Surg
Oncol. 17:1168–1176. 2010.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Ozer M and Goksu SY: Age-dependent
prognostic value of KRAS mutation in metastatic colorectal cancer.
Future Oncol. 17:4883–4893. 2021.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Saltz LB, Lenz HJ, Kindler HL, Hochster
HS, Wadler S, Hoff PM, Kemeny NE, Hollywood EM, Gonen M, Quinones
M, et al: Randomized phase II trial of cetuximab, bevacizumab, and
irinotecan compared with cetuximab and bevacizumab alone in
irinotecan-refractory colorectal cancer: The BOND-2 study. J Clin
Oncol. 25:4557–4561. 2007.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Yoon HH, Tougeron D, Shi Q, Alberts SR,
Mahoney MR, Nelson GD, Nair SG, Thibodeau SN, Goldberg RM, Sargent
DJ, et al: KRAS codon 12 and 13 mutations in relation to
disease-free survival in BRAF-wild-type stage III colon cancers
from an adjuvant chemotherapy trial (N0147 alliance). Clin Cancer
Res. 20:3033–3043. 2014.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Sinicrope FA, Mahoney MR, Yoon HH, Smyrk
TC, Thibodeau SN, Goldberg RM, Nelson GD, Sargent DJ and Alberts
SR: Alliance for Clinical Trials in Oncology. Analysis of molecular
markers by anatomic tumor site in stage III colon carcinomas from
adjuvant chemotherapy trial NCCTG N0147 (Alliance). Clin Cancer
Res. 21:5294–5304. 2015.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Scott A, Goffredo P, Ginader T, Hrabe J,
Gribovskaja-Rupp I, Kapadia MR, Weigel RJ and Hassan I: The Impact
of KRAS mutation on the presentation and prognosis of
non-metastatic colon cancer: An Analysis from the National Cancer
Database. J Gastrointest Surg. 24:1402–1410. 2020.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Shen Y, Han X, Wang J, Wang S, Yang H, Lu
SH and Shi Y: Prognostic impact of mutation profiling in patients
with stage II and III colon cancer. Sci Rep.
6(24310)2016.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Roth AD, Tejpar S, Delorenzi M, Yan P,
Fiocca R, Klingbiel D, Dietrich D, Biesmans B, Bodoky G, Barone C,
et al: Prognostic role of KRAS and BRAF in stage II and III
resected colon cancer: Results of the translational study on the
PETACC-3, EORTC 40993, SAKK 60-00 trial. J Clin Oncol. 28:466–474.
2010.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Gavin PG, Colangelo LH, Fumagalli D,
Tanaka N, Remillard MY, Yothers G, Kim C, Taniyama Y, Kim SI, Choi
HJ, et al: Mutation profiling and microsatellite instability in
stage II and III colon cancer: An assessment of their prognostic
and oxaliplatin predictive value. Clin Cancer Res. 18:6531–6541.
2012.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Ogino S, Meyerhardt JA, Irahara N,
Niedzwiecki D, Hollis D, Saltz LB, Mayer RJ, Schaefer P, Whittom R,
Hantel A, et al: KRAS mutation in stage III colon cancer and
clinical outcome following intergroup trial CALGB 89803. Clin
Cancer Res. 15:7322–7329. 2009.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Juárez M, Egoavil C, Rodríguez-Soler M,
Hernández-Illán E, Guarinos C, García-Martínez A, Alenda C,
Giner-Calabuig M, Murcia O, Mangas C, et al: KRAS and BRAF somatic
mutations in colonic polyps and the risk of metachronous neoplasia.
PLoS One. 12(e0184937)2017.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Chan TL, Zhao W, Leung SY and Yuen ST:
Cancer Genome Project. BRAF and KRAS mutations in colorectal
hyperplastic polyps and serrated adenomas. Cancer Res.
63:4878–4881. 2003.PubMed/NCBI
|
|
27
|
Kuipers EJ, Grady WM, Lieberman D,
Seufferlein T, Sung JJ, Boelens PG, van de Velde CJ and Watanabe T:
Colorectal cancer. Nat Rev Dis Primers. 1(15065)2015.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Shussman N and Wexner SD: Colorectal
polyps and polyposis syndromes. Gastroenterol Rep (Oxf). 2:1–15.
2014.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Bond JH: Colon polyps and cancer.
Endoscopy. 35:27–35. 2003.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Boutin AT, Liao WT, Wang M, Hwang SS,
Karpinets TV, Cheung H, Chu GC, Jiang S, Hu J, Chang K, et al:
Oncogenic Kras drives invasion and maintains metastases in
colorectal cancer. Genes Dev. 31:370–382. 2017.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Ta TV, Nguyen QN, Chu HH, Truong VL and
Vuong LD: RAS/RAF mutations and their associations with epigenetic
alterations for distinct pathways in Vietnamese colorectal cancer.
Pathol Res Pract. 216(152898)2020.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Nguyen HT, Le DT, Duong QH, Tatipamula VB
and Van Nguyen B: High frequency of microsatellite instability and
its substantial co-existence with KRAS and BRAF mutations in
Vietnamese patients with colorectal cancer. Oncol Lett.
21(41)2021.PubMed/NCBI View Article : Google Scholar
|
|
33
|
Sakin A, Arici S, Secmeler S, Can O,
Geredeli C, Yasar N, Demir C, Demir OG and Cihan S: Prognostic
significance of primary tumor localization in stage II and III
colon cancer. World J Gastrointest Oncol. 10:410–420.
2018.PubMed/NCBI View Article : Google Scholar
|
|
34
|
Nagtegaal ID, Odze RD, Klimstra D, Paradis
V, Rugge M, Schirmacher P, Washington KM, Carneiro F and Cree IA:
WHO Classification of Tumours Editorial Board. The 2019 WHO
classification of tumours of the digestive system. Histopathology.
76:182–188. 2020.PubMed/NCBI View Article : Google Scholar
|
|
35
|
GmbH VD. KRAS XL StripAssay: 2020
[updated; cited]. Available from: https://www.goffinmoleculartechnologies.com/wp-content/uploads/2021/04/5680A-InstructionsForUse-2020-01.pdf.
|
|
36
|
Abd El Kader Y, Emera G, Safwat E, Kassem
HA and Kassem NM: The KRAS StripAssay for detection of KRAS
mutation in Egyptian patients with colorectal cancer (CRC): A pilot
study. J Egypt Natl Canc Inst. 25:37–41. 2013.PubMed/NCBI View Article : Google Scholar
|
|
37
|
Formica V and Sera F: KRAS and BRAF
Mutations in Stage II and III colon cancer: A systematic review and
meta-analysis. J Natl Cancer Inst. 114:517–527. 2022.PubMed/NCBI View Article : Google Scholar
|
|
38
|
Aoki Y, Niihori T, Narumi Y, Kure S and
Matsubara Y: The RAS/MAPK syndromes: Novel roles of the RAS pathway
in human genetic disorders. Hum Mutat. 29:992–1006. 2008.PubMed/NCBI View Article : Google Scholar
|
|
39
|
Jin CE, Yeom SS, Koo B, Lee TY, Lee JH,
Shin Y and Lim SB: Rapid and accurate detection of KRAS mutations
in colorectal cancers using the isothermal-based optical sensor for
companion diagnostics. Oncotarget. 8:83860–83871. 2017.PubMed/NCBI View Article : Google Scholar
|
|
40
|
Guo TA, Wu YC, Tan C, Jin YT, Sheng WQ,
Cai SJ, Liu FQ and Xu Y: Clinicopathologic features and prognostic
value of KRAS, NRAS and BRAF mutations and DNA mismatch repair
status: A single-center retrospective study of 1,834 Chinese
patients with Stage I-IV colorectal cancer. Int J Cancer.
145:1625–1634. 2019.PubMed/NCBI View Article : Google Scholar
|
|
41
|
Cienfuegos JA, Baixauli J, Arredondo J,
Pastor C, Martínez Ortega P, Zozaya G, Martí-Cruchaga P and
Hernández Lizoáin JL: Clinico-pathological and oncological
differences between right and left-sided colon cancer (stages
I-III): Analysis of 950 cases. Rev Esp Enferm Dig. 110:138–144.
2018.PubMed/NCBI View Article : Google Scholar
|
|
42
|
Xie MZ, Li JL, Cai ZM, Li KZ and Hu BL:
Impact of primary colorectal Cancer location on the KRAS status and
its prognostic value. BMC Gastroenterol. 19(46)2019.PubMed/NCBI View Article : Google Scholar
|
|
43
|
Mejri N, Dridi M, El Benna H, Labidi S,
Daoud N and Boussen H: Tumor location impact in stage II and III
colon cancer: Epidemiological and outcome evaluation. J
Gastrointest Oncol. 9:263–268. 2018.PubMed/NCBI View Article : Google Scholar
|
|
44
|
Salem ME, Weinberg BA, Xiu J, El-Deiry WS,
Hwang JJ, Gatalica Z, Philip PA, Shields AF, Lenz HJ and Marshall
JL: Comparative molecular analyses of left-sided colon, right-sided
colon, and rectal cancers. Oncotarget. 8:86356–86368.
2017.PubMed/NCBI View Article : Google Scholar
|
|
45
|
Charlton ME, Kahl AR, Greenbaum AA,
Karlitz JJ, Lin C, Lynch CF and Chen VW: KRAS testing, tumor
location, and survival in patients with stage IV colorectal cancer:
SEER 2010-2013. J Natl Compr Canc Netw. 15:1484–1493.
2017.PubMed/NCBI View Article : Google Scholar
|
|
46
|
Natsume S, Yamaguchi T, Takao M, Iijima T,
Wakaume R, Takahashi K, Matsumoto H, Nakano D, Horiguchi SI,
Koizumi K and Miyaki M: Clinicopathological and molecular
differences between right-sided and left-sided colorectal cancer in
Japanese patients. Jpn J Clin Oncol. 48:609–618. 2018.PubMed/NCBI View Article : Google Scholar
|
|
47
|
Dinu D, Dobre M, Panaitescu E, Bîrlă R,
Iosif C, Hoara P, Caragui A, Boeriu M, Constantinoiu S and
Ardeleanu C: Prognostic significance of KRAS gene mutations in
colorectal cancer-preliminary study. J Med Life. 7:581–587.
2017.PubMed/NCBI
|
